India, Oct. 21 -- The U.S. Food and Drug Administration has approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA's Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.
"Menopause is a universal experience for women, and it can greatly affect a person's quality of life. This approval makes effective treatment more accessible," said Acting FDA Commissioner Kyle Diamantas. "Approvals like this reflect FDA's ongoing commitment to expanding American patient access to safe, affordable, high-quality medications."
The generic estradio...